Safety of an Intravitreal Injection of Triamcinolone: Results from a Randomized Clinical Trial

Archives of Ophthalmology

Volumn 122, Issue 3, 2004, Pages 336-340

  Gillies, Mark C ^a,c   Simpson, Judy M ^b   Billson, Frank A ^a   Luo, Wei ^a   Penfold, Philip ^a   Chua, William ^a   Mitchell, Paul ^a   Zhu, Meidong ^a   Hunyor, Alex B L ^c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PLACEBO; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE;

AGED; ARTICLE; CATARACT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA VEIN OCCLUSION; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL IMPAIRMENT;

AGED; AGED, 80 AND OVER; CATARACT; CHOROIDAL NEOVASCULARIZATION; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; HUMANS; INJECTIONS; INTRAOCULAR PRESSURE; MACULAR DEGENERATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SAFETY; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY; VITREOUS BODY;

EID: 1542317855     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.122.3.336     Document Type: Article

References (27)

1. Coles RS, Krohn DL, Breslin H, Braunstein R. Depo-Medrol in treatment of inflammatory diseases of the anterior segment of the eye. Am J Ophthalmol. 54:407-411.
2. Sturman RM, Laval J, Sturman MF. Subconjunctival triamcinolone acetonide. Am J Ophthalmol. 1966;61:155-166.
3. McCluskey P, Forrester J, Lightman S. Uniocular macular oedema arid reduced vision in a patient with uveitis. Clin Experiment Ophthalmol. 2000;28:9-12.
4. Gillies MG, Simpson JM, Luo W, et al. A randomized clinical trial of a single dose of triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol. 2003;121:667-673.
5. Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and triamcinolone: a pilot study. Aust N Z J Ophthalmol. 1995;23: 293-298.
6. Wingate RJ, Beaumont PE. Intravitreal triamcinolone and elevated intraocular pressure. Aust N Z J Ophthalmol. 1999;27:431-432.
7. Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Experiment Ophthalmol. 2001;29:2-6.
8. Sutter FK, Ges MC. Pseudo-endophthalmitis after intravitreal injection of triamcinolone. Br J Ophthalmol. 2003;87:972-974.
9. Scholes GN, O'Brien WJ, Abrams GW, Kubicek MF. Clearance of triamcinolone from vitreous. Arch Ophthalmol. 1985;103:1567-1569.
10. Schindler RH, Chandler D, Thresher R, Machemer R. The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol. 1982;93:415-417.
11. Kalina PH, Erie JC, Rosenbaum L. Biochemical quantification of triamcinolone in subconjunctival depots. Arch Ophthalmol. 1995;113:867-869.
12. Mills DW, Siebert LF, Climenhaga DB. Depot triamcinolone-induced glaucoma. Can J Ophthalmol. 1986;21:150-152.
13. Mueller AJ, Jian G, Banker AS, Rahhal FM, Capparelli E, Freeman WR. The effect of deep posterior subtenon injection of corticosteroids on intraocular pressure. Am J Ophthalmol. 1998;125:158-163.
14. Herschler J. Increased intraocular pressure induced by repository corticosteroids. Am J Ophthalmol. 1976;82:90-93.
15. Helm CJ, Holland GN. The effects of posterior subtenon injection of triamcinolone. Am J Ophthalmol. 1995;120:55-64.
16. Morgan CM, Schatz H, Vine AK, et al. Ocular complications associated with retrobulbar injections. Ophthalmology. 1988;95:660-665.
17. Ellis PP. Occlusion of the central retinal artery after retrobulbar corticosteroid injection. Am J Ophthalmol. 1978;85:352-356.
18. Giles CL. Bulbar perforation during periocular injection of corticosteroids. Am J Ophthalmol. 1974;77:438-441.
19. Yang CS, Khawly JA, Hainsworth DP, et al. An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch Ophthalmol. 1998;116:69-77.
20. Danis RP, Bingaman DP, Yang Y, Ladd B. Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology. 1996;103:2099-2104.
21. Antoszyk AN, Gottlieb JL, Machemer R, Hatchell DL. The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization. Graefes Arch Clin Exp Ophthalmol. 1993;231:34-40.
22. Chandler DB, Hida T, Sheta S, Proia AD, Machemer R. Improvement in efficacy of corticosteroid therapy in an animal model of proliferative vitreoretinopathy by pretreatment. Graefes Arch Clin Exp Ophthalmol. 1987;225:259-265.
23. Ciulla TA, Criswell MH, Danis RP, Hill TE. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol. 2001;119:399-404.
24. Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, Ffytche TJ, Marshall J. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology. 2001;108:765-772.
25. Martidis A, Duker JS, Puliafito CA. Intravitreal triamcinolone for refractory cystoid macular edema secondary to birdshot retinochoroidopathy. Arch Ophthalmol. 2001;119:1380-1383.
26. Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol. 2001;132:425-427.
27. Jonas JB, Hayler JK, Sofker A, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol. 2001;131:468-471.